Summary A novel resistant variant of murine P388 leukaemia, P388/SPR, was identified by de novo resistance to doxorubicin (DOX) in vivo. This mutant displayed a similar level of cross-resistance to etoposide (VP-16) and other topoisomerase 11 (topo 11) inhibitors. Further analysis of the phenotype revealed a broad cross-resistance to vinca alkaloids, alkylating agents, antimetabolites, aphidicolin and UV light. Low-level expression of mdrl and P-glycoprotein (P-gp), as well as a modest impairment of cellular drug accumulation and partial reversion of resistance to DOX and VP-1 6 by cyclosporine, confirmed a moderate role of P-gp in conferring drug resistance in P388/SPR cells. Consistent changes in neither topo 11 expression or activity nor glutathione metabolism could be detected. Induction of apoptosis was significantly reduced in P388/SPR cells, as indicated by minimal DNA fragmentation. Analysis of oncogenes regulating apoptotic cell death revealed a marked decrease of bcl-2 in combination with a moderate reduction of bax protein, but a striking overexpression of the long form of the bcl-X protein. Transfection of human bcl-X-L into P388 cells conferred drug resistance similar to that of P388/SPR cells. The data suggest that overexpression of bcl-X-L results in an unusual phenotype with broad cross-resistance to non-MDR-related cytotoxins in vitro, and provide an interesting example of spontaneous overexpression of another member of the bcl-2 gene family in cancer.
The mechanisms of action of doxorubicin (DOX) are complex and include free radical formation (Bachur et al, 1978) , membrane effects (Tritton et al, 1978) , DNA intercalation and disruption of topoisomerase II (topo II) action (Tewey et al, 1984) , as well as induction of apoptosis (Ling et al, 1993) . P-glycoprotein (P-gp) and changes in topo II expression or activity are well-known mechanisms of resistance to DOX (Kartner et al, 1985; Deffie et al, 1989; Ganapathi et al, 1989; Baas et al, 1990 ) (for review see Endicott and Ling, 1989; Hochhauser and Harris, 1993) . Other alternative mechanisms include increased glutathione (GSH) levels (Kramer et al, 1988; Rabier et al, 1991) or glutathione-S-transferase (GST) activity (Nakagawa et al, 1990) and inhibition of programmed cell death by overexpression of bcl-2 or loss of p53 (Lowe et al, 1993; Miyashita and Reed, 1993) . Resistance to DOX may be multifactorial, with several of these mechanisms involved (Baas et al, 1990; Rabier et al, 1991; Datta et al, 1995) .
The aforementioned mechanisms have predominantly been studied in cell lines purposely rendered resistant by treatment with increasing drug concentrations in vitro. We report herein a novel resistance phenotype of a variant of the murine P388 leukaemia, which was observed to be resistant to DOX after in vivo passaging without drug selection. Analysis of these drug-resistant leukaemia cells revealed marked overexpression of bcl-X-L, thus providing an example of spontaneously occurring deregulated bcl-X-L expression in association with chemoresistance in cancer.
MATERIALS AND METHODS Drugs and chemicals
The drugs used in this study and their sources are as follows: etoposide (VP-16) and cisplatin (Bristol Laboratories, Syracuse, NY, USA), doxorubicin (DOX; Adria Laboratories, Columbus, OH, USA), vinblastine (Eli Lilly, Indianapolis, IN, USA), cytarabine (Ara C; Upjohn, Kalamazoo, MI, USA), mitoxantrone (Lederle Laboratories, Pearl River, NY, USA), 4-hydroperoxycyclophosphamide (4-OH-cyclophosphamide; Nova Pharmaceuticals, Baltimore, MD, USA) and cyclosporine (Basle, Switzerland).
Camptothecin and amsacrine (generously provided by Dr DOX in vivo (Dr David Streeter, personal communication) . Aliquots of P388/SPR cells that had not been exposed to drug before were used for the in vitro characterization. These cells were not cloned. The P-gp-positive 'classical' MDR subline P388/ADR was obtained from Dr J G Mayo (National Cancer Institute, Frederick, MD, USA). The identical origin of these lines was confirmed by karyotype analysis, H2-phenotyping and restriction fragment length polymorphism (RFLP) of the highly polymorphic D-loop region of mitochondrial DNA (data not shown). Cells were maintained in vitro as standard suspension cultures as described (Kuhl et al, 1993) .
For transfection studies, parental P388 cells were electroporated with the BCMGS-Neo plasmid with or without human bcl-X cDNA (Kuhl et al, manuscript in preparation) . Transfectants were selected for neomycin resistance and stable clones were obtained by limited dilution. A clone overexpressing bcl-X-L protein by at least five fold was used for cytotoxicity experiments.
MTT cytotoxicity assays Drug sensitivity was compared employing the MUT cytotoxicity assay after a 48-h (approximately four generation times) drug incubation period as previously described (Kuhl et al, 1993) . IC50 values were calculated from semilogarithmic dose-response curves by linear interpolation.
Accumulation studies Uptake of radioactivity by P388/SPR cells in comparison with parental P388 cells incubated in 100 nM [3H]vinblastine at 37°C was studied according to the method previously described (Lau et al, 1991) .
Western blot analysis
Standard denaturing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting for P-gp and GSTs were done as described (Lau et al, 1991) using the Pgp-detecting antibody C219 (Kartner et al, 1985) or specific rabbit GST antibodies raised against the human 7i class GST (X, YfYf subunits) as well as human a class GST (B, B1, YaYa subunit) respectively. Samples for detection of topo II were prepared and Western blots carried out as described before (Drake et al, 1987) . Antibodies against both isoforms of human topo II were generously provided by Dr F Drake (Smith Kline, King of Prussia, PA, USA). Polyclonal rabbit antibodies against murine bcl-2, bax and bcl-X were raised and immunoblots performed as described (Krajewski et al, , 1996 . Specific bands were quantitated using the integrated image analysis system MicroComp from Southern Micro Instruments (Atlanta, GA, USA).
Immunocytochemistry
Approximately 5 x 104 cells were applied to glass slides by cytocentrifugation, air dried and fixed in 4% acetone. The slides were rinsed with phosphate-buffered saline (PBS) and incubated with monoclonal antibodies against P-gp (C219; Centocor, Malvern, PA, USA), wild-type and mutant p53 (PAb 421 and PAb 240; Oncogene Science, Uniondale, NY, USA), c-myc (LA 070; Quality Biotech, Camden, NJ, USA) and the retinoblastoma gene (RB-PMG3-245; PharMingen, San Diego, CA, USA). Following incubation with a secondary biotin-conjugated goat anti-mouse antibody (Jackson Immunoresearch Laboratories, West Grove, PA, USA), slides were developed by a standard streptavidin-horseradish peroxidase method (Jackson). Immunocytochemistry for bcl-2 and bcl-X was done as described (Hanada et al, 1993) . Cells were counterstained with methyl blue or green. For bcl-2 family proteins, either the antisera after peptide competition or preimmune rabbit sera served as appropriate controls. In all other experiments, PBS instead of the primary antibody was used as negative control. Varying dilutions of primary antibody were compared, and slides were scored by three different investigators as negative, one, two or three plus.
Polymerase chain reaction (PCR) studies
Gene expression of mdrl, topo IIa, topo II,B and bcl-2 was semiquantitatively determined similar to the method described by Noonan et al (1988) . cDNA was synthesized from total cellular RNA using random hexadeoxynucleotide primers (Pharmacia, Milwaukee, WI, USA). Primers used were derived from human sequences as follows (numbers refer to GenBank positions): 5' (3020-3037), 3' (3168-3187) for mdrl; 5' (1136-1163), 3' (1649-1676) for topo IIa; 5' (2079 -2102 , 3' (2359-2382) for topo IlI; 5' (104-124), 3' (456-476) for bcl-2; and 5' (1501-1520), 3' (1827-1846) for 28S rRNA. Each primer set detected highly homologous fragments of identical length to the corresponding murine genes. Serial dilutions of cDNA were used as template to assure amplification within a linear range and PCR was carried out using standard conditions as described before (Brophy et al, 1994) . Quantitation was done by incorporation of [e-32P]dCTP and gene expression was standardized on the basis of 28S rRNA message as an index of total cellular RNA content. Negative controls using water instead of template were included in all experiments. The ratio of specific gene expression (background subtracted) vs rRNA message was calculated and arbitrarily set to 100 units for P388/ADR (mdrl) or for P388 cells (topo Ia3p, bcl-2).
K-SDS precipitation assay for protein-DNA complexes
The in vitro formation of covalent topoisomerase-DNA complexes, so-called cleavable complexes, was quantitated to assess topoisomerase activity. Cells in early log phase (2 x 105 cells per ml) were prelabelled with [methyl-3H] thymidine at a final concentration of 0.5 ,uCi ml-' for 24 h. Harvested cells were washed and nuclei were isolated as described (Ganapathi et al, 1989) . Nuclei were treated with various concentrations of VP-16 in the presence of ATP (1 mM) or with camptothecin in the absence of ATP for 30 min at 37°C respectively. Nuclei were then lysed and processed as reported (Rowe et al, 1986) . The percentage of specifically precipitated DNA was calculated.
Glutathione and glutathione-dependent enzyme measurements Cells were harvested in mid-log phase (approximately 5 x l05 cells per ml) and washed twice in PBS. For the analysis of GSH, cells were extracted in 20 mm 5-sulphosalicylic acid and samples stored at 4°C. GSH was later determined by high-performance liquid chromatography (HPLC) using monobromobimane as described (Minchinton, 1984) . For GST activities, cells were sonicated, centrifuged and the activity toward CDNB in the supematant was assayed as described (Lau et al, 1991) . 
Statistical analysis
Significance levels of mRNA and protein quantitation were calculated using the Mann-Whitney U-test. Significance of all other data was tested by a two-tailed Student's t-test.
RESULTS

Phenotypic characterization
The P388/SPR subline was phenotypically characterized by its cross-resistance pattern to different cytotoxic drugs. The results of MTT assays after a 48-h drug incubation period are summarized in Table 1 . P388/SPR cells displayed the highest degree of resistance to DOX and to VP-16. Both could be partially reversed (twofold)
by the addition of 2.5 tM cyclosporine. To a somewhat lesser degree, cross-resistance was also observed for other topo II inhibitors, such as amsacrine and mitoxantrone. The relative low resistance levels of P388/SPR cells in comparison with the Pgp-positive P388/ADR subline, especially the low degree of crossresistance to vinblastine (threefold) and the partial sensitization by cyclosporine (modulation factor of 2), suggested a limited role of mdrl-mediated resistance in this variant. In contrast to the P388/ADR variant, however, P388/SPR cells displayed significant cross-resistance to cross-linking agents, such as cisplatin and 4-OH-cyclophosphamide, to the topoisomerase I inhibitor camptothecin, to the antimetabolite cytarabine, to aphidicolin, an inhibitor of DNA polymerase oc, as well as to UV light. Figure 2B ). The K-SDS assay, which measures the formation of cleavable complexes, was employed to detect topo II activity. These experiments were performed on isolated nuclei in the presence of 1 mm ATP to exclude any differences in cellular drug accumulation. There was a dose-dependent, VP-16-induced formation of cleavable complexes in both cell lines with no detectable differences (data not shown). Similar experiments using camptothecin in the absence of ATP indicated no difference in the topoisomerase I activity of P388 and P388/SPR cells also.
GSH and expression of GSTs
The GSH content in P388/SPR cells was 3.3 ± 0.3 fmol per cell (mean ± s.d.), which is about 50% greater than in P388 cells that contained 2.2 ± 0.5 fmol per cell (P<0.05). In contrast, the P388/SPR variant displayed with 68 ± 6 nmol min-' mg-' protein a significant decrease in total GST activity compared with 111 ± 14 nmol min-m mg-' protein in P388 cells. Quantification of the protein expression of GST-x and GST-ir subclasses implied that the difference is caused by a corresponding decrease in GST-ir protein levels of about 60% relative to the parental cells.
Expression of oncogenes regulating apoptotic cell death and measurement of induction of apoptosis
We measured the protein expression of some tumour-suppressor genes and oncogenes implicated in the regulation of apoptosis and cell growth. Western blot analysis of the expression of bcl-2 and related proteins is shown in Figure 3 . By the technique used, bcl-2 protein was not detectable in P388/SPR cells in contrast to easily detectable levels in the parental cells ( Figure 3A ). This was in agreement with a significant decrease of bcl-2 mRNA expression igure 4 Immunocytochemistry for bcl-X in P388 (A) and P388/SPR cells (B). Cells were counterstained with methyl green; magnification 1000-fold. Contrary to the absence of bcl-X in parental cells (A), a striking overexpression of bcl-X was detected predominantly in large, differentiated mutant cells (B) to 23% of the level of P388 cells (data not shown). The expression of bax protein was reduced by approximately 40% in P388/SPR cells compared with the parental cells. In contrast, a significant overexpression of bcl-X-L protein by a median factor of 9.7 could be detected in this subline ( Figure 3B ). Especially larger, more differentiated cells of the P388/SPR subline displayed a striking cytoplasmic overloading with bcl-X ( Figure 4B ). All semiquantitative results of immunocytochemistry are summarized in Table 2 . In addition to the differences in the expression of bcl-2 and related proteins, the c-myc protein was slightly elevated and the retinoblastoma gene product reduced in the P388/SPR variant. All cell lines expressed the mutant p53 protein at similar levels.
To assess cytotoxin-induced apoptosis, a quantitative ELISA measuring cytoplasmic DNA-histone complexes (nucleosomes) was used. Apoptotic DNA fragmentation in P388 cells was readily induced by DOX ( Figure 5A ) and cisplatin ( Figure SB) , whereas nucleosomes in P388/SPR cells were virtually undetectable within a 6-h period.
Transfection of Bcl-X-L into P388 cells To confirm the role of bcl-X in modulating chemoresistance, human bcl-X cDNA was transfected into P388 cells. The data are summarized in Table 3 . In comparison to the 'mock' transfected P388/Neo cells, the bcl-X-L overexpressing clone displayed a relatively high level of cross-resistance to cisplatin and an intermediate level of resistance to DOX, VP-16 and to 4-OH-cyclophosphamide. Crossresistance to vinblastine was marginal. Given the contributory role of P-gp in the P388/SPR variant, the overall cross-resistance pattern was similar to that of the P388/SPR cells.
DISCUSSION
The spontaneously resistant variant of murine P388 leukaemia is characterized by an unusual phenotype with cross-resistance to many non-MDR-related cytotoxins, such as the topoisomerase I inhibitor camptothecin, alkylators, aphidicolin and UV light. The major alteration in gene expression, which was found associated with this phenotype, is the striking overexpression of the long form of the bcl-X protein. The bcl-X gene encodes two proteins with opposing effects on apoptosis via an alternative splicing mechanism (Boise et al, 1993) . The larger of these, bcl-X-L, is a blocker of apoptosis like bcl-2, whereas the shorter, bcl-X-S, accelerates cell death rates. Accordingly, bcl-X-L does confer chemoresistance (Minn et al, 1995) , whereas bcl-X-S sensitizes cells to chemotherapy as has been demonstrated by recent transfection studies (Sumantran et al, 1995) . Both DOX and VP-16 induce apoptosis (Ling et al, 1993; Lowe et al, 1993) . Several oncogenes and tumour-suppressor genes have been identified that regulate the apoptotic cell death, including bcl-2 and related proteins, c-myc and p53 (for review see Reed, 1994;  Thompson, 1995) . Overexpression of the 26-kDa bcl-2 protein in transfected cell lines prevents apoptosis and confers resistance to a number of cytotoxic anti-cancer agents, including topo II inhibitors (Miyashita and Reed, 1993) . bcl-2 forms heterodimers with the 21 -kDa protein bax, which counters the death-repressor activity of bcl-2 (Oltvai et al, 1993) . Moreover, the bcl-2 protein functionally interacts with c-myc by specifically abrogating cmyc-induced apoptosis without affecting its mitogenic function (Fanidi et al, 1992) . Similarly, wild-type p53 plays a crucial role in the execution of apoptosis after DNA damage induced by radiation and chemotherapeutic drugs (Clarke et al, 1993) and bcl-2 has been shown to block p53-induced cell death (Miyashita et al, 1994) . All three P388 sublines expressed mutant p53 at similar levels by immunocytochemistry. The P388/SPR variant demonstrated a significantly decreased expression of bcl-2 mRNA, and bcl-2 protein was not detectable by Western blotting. Although bax protein expression was also slightly reduced, the ratio of bax to bcl-2 was still clearly higher than in the parental cells, which by itself might suggest a tendency to a reduced survival of P388/SPR cells according to a proposed model (Oltvai et al, 1993) . This apparent contradiction might be explained by the finding that bel-X-L, but not bcl-X-S, also heterodimerizes with bax and opposes bax-induced cell death (Sato et al, 1994) . When considered the dominant role of bcl-X-L, which is in agreement with data from previous studies of bcl-X-L (Sato et al, 1994; Minn et al, 1995; Datta et al, 1995) , the finding of overexpression of bcl-X-L is highly likely to contribute to the resistant phenotype of these cells. Moreover, transfection of bcl-X-L into P388 cells resulted in a similar phenotype with broad cross-resistance.
Several findings suggest a contributory but limited role of mdrl for the resistance phenotype of P388/SPR cells: (1) this mutant displays some cross-resistance to vinca-alkaloids; (2) the addition of the MDR modulator cyclosporine had a minimal effect on DOX and VP-16 resistance; (3) the degree of impairment in accumulation of vinblastine is modest; and (4) in contrast to the wild-type P388 cells, mdrl and P-gp expression was detectable in P388/SPR cells, but very low compared with the classical MDR variant, P388/ADR.
We could not detect consistent changes of topo II or GSH metabolism in P388/SPR cells. In the case of topo II, no significant reduction of mRNA levels of both isoforms or decreased formation of cleavable complexes could be observed in P388/SPR cells compared with P388 cells. Although topo Ila protein levels appeared to be decreased in this variant, topo IIlB levels were increased and have been shown to have significance in conferring drug resistance (Harker et al, 1991) . In addition, decatenation activity in nuclear extracts from both cell lines was similar (J-S KOhl, unpublished data).
As suggested by karyotypic analysis, P388/SPR cells emerged from clonal expansion during repeated in vivo passaging without prior drug selection (Dr David Streeter, personal communication). No growth advantage of P388/SPR cells could be observed in vitro; however, the cells were more resistant to overgrowth and serum deprivation (J-S Kuhl, unpublished data). Therefore, it might be speculated that the observed overexpression of the bel-X-L and c-myc proteins, as well as decreased levels of the retinoblastoma gene product, conferred some survival advantage in vivo that presumably permitted this variant to replace the parental P388 cells. Although the resistance mechanisms involved in P388/SPR cells may be multifactorial, the striking overexpression of bcl-X-L observed in these cells may provide an explanation for the novel phenotype of this drug-resistant variant. The P388/SPR cell line serves as an interesting example of spontaneously occurring overexpression of bcl-X-L in association with broad cross-resistance to anti-tumour agents.
ABBREVIATIONS
Bax, bcl-2-associated X protein; bcl-X-L, long form of bcl-X; DOX, doxorubicin; GSH, glutathione; GST, glutathione-S-transferase; IC50, drug concentration which reduces specific absorbance to 50% of control levels; MDR, multidrug resistance; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolin bromide; PBS, phosphate-buffered saline; P-gp, P-glycoprotein; RT-PCR, reverse transcription-polymerase chain reaction; topo II OtJ3, topoisomerase II ax (1 70-kDa isoform)/P (1 80-kDa isoform); etoposide. 
